Trial Profile

LARCID: Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 May 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Octreotide (Primary)
Indications Diarrhoea
Focus Therapeutic Use
Acronyms LARCID
Sponsors Novartis Pharma A.G.

Most Recent Events

02 Apr 2014 Integrated data from ClinicalTrials.gov.
02 Apr 2014 New trial record
10 Feb 2014 Results published in the Journal of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com